We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Market Dipped But DaVita HealthCare (DVA) Gained Today
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $217.04, moving +1.72% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 0.05%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 0.24%.
Shares of the kidney dialysis provider have appreciated by 8.25% over the course of the past month, outperforming the Medical sector's gain of 4.42%, and the S&P 500's loss of 1.42%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is forecasted to report an EPS of $4.01, showcasing a 35.93% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 billion, up 4.53% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $15.07 per share and revenue of $14.3 billion. These totals would mark changes of +39.8% and +4.78%, respectively, from last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare is holding a Zacks Rank of #1 (Strong Buy) right now.
Looking at valuation, DaVita HealthCare is presently trading at a Forward P/E ratio of 14.16. Its industry sports an average Forward P/E of 19.05, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
We can also see that DVA currently has a PEG ratio of 0.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.6 as trading concluded yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 69, placing it within the top 29% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why the Market Dipped But DaVita HealthCare (DVA) Gained Today
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $217.04, moving +1.72% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 0.05%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 0.24%.
Shares of the kidney dialysis provider have appreciated by 8.25% over the course of the past month, outperforming the Medical sector's gain of 4.42%, and the S&P 500's loss of 1.42%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is forecasted to report an EPS of $4.01, showcasing a 35.93% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 billion, up 4.53% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $15.07 per share and revenue of $14.3 billion. These totals would mark changes of +39.8% and +4.78%, respectively, from last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare is holding a Zacks Rank of #1 (Strong Buy) right now.
Looking at valuation, DaVita HealthCare is presently trading at a Forward P/E ratio of 14.16. Its industry sports an average Forward P/E of 19.05, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
We can also see that DVA currently has a PEG ratio of 0.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.6 as trading concluded yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 69, placing it within the top 29% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.